Last updated: February 24, 2026
What is the Drug Identified by NDC 73515-0123?
NDC 73515-0123 corresponds to Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for treating type 2 diabetes mellitus. It is marketed under the brand name Steglatro by Merck & Co.
Market Overview
Market Size and Growth Rate
The global type 2 diabetes medication market was valued at approximately $50 billion in 2022. The SGLT2 inhibitor segment accounts for roughly 25% of this market:
| Metric |
Data |
| Total market (2022) |
$50 billion |
| SGLT2 inhibitors share |
25% ($12.5 billion) |
| Estimated growth rate |
8-10% CAGR (2023-2028) |
Competitive Landscape
Major competitors include:
- Jardiance (empagliflozin) — marketed by Boehringer Ingelheim and Eli Lilly
- Invokana (canagliflozin) — marketed by Janssen Pharmaceuticals
- Farxiga (dapagliflozin) — marketed by AstraZeneca
Ertugliflozin's market share remains limited relative to Jardiance and Farxiga, which have broader indication updates.
Key Drivers
- Increasing prevalence of type 2 diabetes globally
- Growing acceptance of SGLT2 inhibitors for cardiovascular and renal benefits
- Expanding indications for cardiovascular outcomes trials
Market Barriers
- Cost of therapy limits prescription adoption
- Concerns over side effects like ketoacidosis and urinary infections
- Patent exclusivity period constraints
Price Analysis
Current Pricing (As of Q1 2023)
- Brand Name (Steglatro): Estimated retail price of $500–$600 per month for a typical dose
- Generic Versions (if available): Price range $250–$350 per month
Pricing Trends
- The brand price has remained relatively stable over the last 12 months
- Launch of generics expected after patent expiry, projected in 2026
Cost Comparison
| Drug |
Approximate Monthly Cost |
Market Status |
| Steglatro |
$500–$600 |
Branded |
| Jardiance |
Similar to Steglatro |
Branded |
| Generic (Projected) |
$250–$350 |
Pending approval |
Price Projections (2024-2028)
| Year |
Expected Range for branded drug |
Rationale |
| 2024 |
$500–$600 |
Stable, no new competitors |
| 2025 |
$530–$620 |
Slight inflation, patents still active |
| 2026 |
$480–$550 |
Introduction of generics, price competition intensifies |
| 2027 |
$350–$450 |
Generics dominate, high competition lowers prices |
Regulatory and Patent Outlook
- Patent expiration anticipated in 2026, enabling entry of generics
- Regulatory agencies will assess indications for expanded uses, influencing pricing and market size
Strategic Considerations
- Merck may pursue premium positioning for specialized indications
- Generic entry will erode margins but expand prescribing volume
- Contracting with payers influences net pricing and reimbursement rates
Key Takeaways
- NDC 73515-0123 (Ertugliflozin) is positioned within a competitive SGLT2 inhibitor market valued at around $12.5 billion annually
- The drug faces competitive pressure from established brands with larger market shares
- Current prices range from $500 to $600 per month, with expected stabilization until patent expiry
- Post-patent expiration in 2026, generic alternatives could reduce prices by approximately 50%
- Market growth will be driven by increasing diabetes prevalence and expanded indications, balancing against pricing pressures
FAQs
1. When will generic versions of ertugliflozin become available?
Patent expiry is anticipated in 2026, with generics expected shortly thereafter.
2. How does the efficacy of ertugliflozin compare with other SGLT2 inhibitors?
Clinical trials show similar efficacy among SGLT2 inhibitors, with some differences in cardiovascular and renal benefits, which influence prescribing choices.
3. What are the primary side effects associated with ertugliflozin?
Risks include urinary tract infections, ketoacidosis, dehydration, and genital infections.
4. How might reimbursement policies change with market entry of generics?
Reimbursement rates are likely to increase, with payers favoring lower-cost generics over branded options, impacting profitability.
5. What are the prospects for expanding ertugliflozin indications?
Regulatory agencies are evaluating evidence for additional indications such as heart failure and chronic kidney disease, which could expand market potential.
References
[1] Marketwatch. (2023). Global diabetes medication market report.
[2] IQVIA. (2022). SGLT2 inhibitors market share analysis.
[3] FDA. (2022). Patent and exclusivity data for ertugliflozin.
[4] EvaluatePharma. (2022). Prescription trends and pricing forecasts for diabetes drugs.
(Note: Data and projections are based on current market reports and should be verified against updated sources upon further review.)
